GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-Center Research

GenFleet Therapeutics announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in a Phase Ib/II trial of GFH018 in combination with toripalimab as part of global multi-center clinical research. There are broad indications for GFH018 in treating solid tumors with lower response rates to PD-1 inhibitors.